IRD
Opus Genetics, Inc.
Price Chart
Latest Quote
$3.72
+0.01 (+0.27%)
Current Price
| Previous Close | $3.71 |
| Open | $3.73 |
| Day High | $3.83 |
| Day Low | $3.62 |
| Volume | 976,526 |
Stock Information
| Shares Outstanding | 82.57M |
| Total Debt | $1.20M |
| Cash Equivalents | $59.96M |
| Revenue | $11.98M |
| Net Income | $-106.93M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $307.14M |
| EPS (TTM) | $-1.31 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $267.95M |
| Sales | $11.98M |
| Income | $-106.93M |
| Book/sh | $-0.64 |
| Cash/sh | $0.73 |
| Employees | 27 |
Financial Ratios
| Quick Ratio | 6.71 |
| Current Ratio | 7.13 |
Returns & Margins
| ROA | -46.79% |
| ROE | -7594.60% |
| Gross Margin | -179.03% |
| Operating Margin | -665.92% |
Ownership
| Insider Ownership | 11.06% |
| Institutional Ownership | 55.02% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.87 |
| P/S | 25.63 |
| P/B | -5.79 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $10.56 |
Technical Indicators
| SMA20 | $4.05 |
| SMA50 | $4.62 |
| SMA200 | $3.21 |
| RSI | 22.94 |
| ATR | 0.2808 |
| Shares Float | 63.40M |
| Short Float | 4.99% |
| Short Ratio | 4.05 |
| Volatility | 0.55 |
| Rel Volume | 1.15 |
Performance History
| Week | -8.37% |
| Month | -9.05% |
| Quarter | -21.68% |
| 6 Months | +80.58% |
| YTD | +75.47% |
| Year | +304.35% |
| 3 Years | -6.30% |
| 5 Years | -24.08% |
| 10 Years | -96.90% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $3.72 | 976,526 |
| 2026-06-24 | $3.71 | 948,900 |
| 2026-06-23 | $4.08 | 726,700 |
| 2026-06-22 | $4.08 | 980,100 |
| 2026-06-18 | $4.07 | 1,056,500 |
| 2026-06-17 | $4.06 | 1,065,300 |
| 2026-06-16 | $3.90 | 766,700 |
| 2026-06-15 | $3.92 | 642,500 |
| 2026-06-12 | $4.04 | 689,900 |
| 2026-06-11 | $3.91 | 553,700 |
| 2026-06-10 | $3.89 | 818,900 |
| 2026-06-09 | $4.08 | 803,700 |
| 2026-06-08 | $4.03 | 536,200 |
| 2026-06-05 | $4.03 | 1,017,100 |
| 2026-06-04 | $4.64 | 1,087,100 |
| 2026-06-03 | $4.20 | 915,900 |
| 2026-06-02 | $3.99 | 952,500 |
| 2026-06-01 | $4.12 | 1,012,400 |
| 2026-05-29 | $4.36 | 977,200 |
| 2026-05-28 | $4.20 | 513,000 |
| 2026-05-27 | $4.14 | 1,056,200 |
| 2026-05-26 | $4.09 | 795,200 |
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
đ° Latest News
Guggenheim Initiates Coverage Of Opus Genetics (IRD) With âBuyâ Rating And $16 Price Target
Insider Monkey âĸ 2026-06-10T18:22:47Z
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
MarketBeat âĸ 2026-05-26T02:02:46Z
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-12T12:20:01Z
Certara, Inc. (CERT) Q1 Earnings Miss Estimates
Zacks âĸ 2026-05-11T11:45:03Z
Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ Stocks
Insider Monkey âĸ 2026-05-05T17:04:53Z
Citizens Initiates Coverage of Opus Genetics (IRD)
Insider Monkey âĸ 2026-05-01T08:18:22Z
BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating
Insider Monkey âĸ 2026-03-12T07:37:59Z
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates
Zacks âĸ 2026-03-10T12:30:02Z
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-03-04T22:10:01Z
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires âĸ 2026-02-13T20:52:38Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $14,196,000 | $10,992,000 | $19,049,000 | $39,850,000 |
| Operating Revenue | $14,196,000 | $10,992,000 | $19,049,000 | $39,850,000 |
| Expenses | ||||
| Interest Expense | $1,466,000 | $0 | $1,328,000 | $9,000 |
| Total Expenses | $52,795,000 | $45,066,000 | $29,612,000 | $21,624,000 |
| Other Income Expense | $-9,526,000 | $-23,458,000 | $1,917,000 | $-14,000 |
| Other Non Operating Income Expenses | $1,989,000 | $4,470,000 | $1,837,000 | $-14,000 |
| Net Non Operating Interest Income Expense | $-1,466,000 | $0 | $-1,328,000 | $-9,000 |
| Interest Expense Non Operating | $1,466,000 | $0 | $1,328,000 | $9,000 |
| Operating Expense | $52,795,000 | $45,066,000 | $29,612,000 | $21,624,000 |
| General And Administrative Expense | $21,983,000 | $18,215,000 | $11,959,000 | $7,269,000 |
| Total Other Finance Cost | - | - | $1,328,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-49,591,000 | $-57,532,000 | $-9,986,000 | $17,888,000 |
| Net Interest Income | $-1,466,000 | $0 | $-1,328,000 | $-9,000 |
| Normalized Income | $-38,076,000 | $-29,604,000 | $-10,049,200 | $17,888,000 |
| Net Income From Continuing And Discontinued Operation | $-49,591,000 | $-57,532,000 | $-9,986,000 | $17,888,000 |
| Total Operating Income As Reported | $-38,599,000 | $-62,074,000 | $-10,563,000 | $18,226,000 |
| Net Income Common Stockholders | $-49,591,000 | $-57,532,000 | $-9,986,000 | $17,888,000 |
| Net Income | $-49,591,000 | $-57,532,000 | $-9,986,000 | $17,888,000 |
| Net Income Including Noncontrolling Interests | $-49,591,000 | $-57,532,000 | $-9,986,000 | $17,888,000 |
| Net Income Continuous Operations | $-49,591,000 | $-57,532,000 | $-9,986,000 | $17,888,000 |
| Pretax Income | $-49,591,000 | $-57,532,000 | $-9,974,000 | $18,203,000 |
| Special Income Charges | $0 | $-28,000,000 | $0 | - |
| Operating Income | $-38,599,000 | $-34,074,000 | $-10,563,000 | $18,226,000 |
| Per Share | ||||
| Diluted EPS | $-0.80 | $-2.15 | $-0.46 | $0.87 |
| Basic EPS | $-0.80 | $-2.15 | $-0.46 | $0.90 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $16,800 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-36,557,000 | $-29,594,000 | $-8,720,000 | $18,216,000 |
| Total Unusual Items | $-11,515,000 | $-27,928,000 | $80,000 | - |
| Total Unusual Items Excluding Goodwill | $-11,515,000 | $-27,928,000 | $80,000 | - |
| Reconciled Depreciation | $53,000 | $10,000 | $6,000 | $4,000 |
| EBITDA (Bullshit earnings) | $-48,072,000 | $-57,522,000 | $-8,640,000 | $18,216,000 |
| EBIT | $-48,125,000 | $-57,532,000 | $-8,646,000 | $18,212,000 |
| Diluted Average Shares | $62,221,901 | $26,715,526 | $21,589,821 | $20,597,212 |
| Basic Average Shares | $62,221,901 | $26,715,526 | $21,589,821 | $19,931,080 |
| Diluted NI Availto Com Stockholders | $-49,591,000 | $-57,532,000 | $-9,986,000 | $17,888,000 |
| Tax Provision | $0 | $0 | $12,000 | $315,000 |
| Gain On Sale Of Security | $-11,515,000 | $72,000 | $80,000 | - |
| Research And Development | $30,812,000 | $26,851,000 | $17,653,000 | $14,355,000 |
| Selling General And Administration | $21,983,000 | $18,215,000 | $11,959,000 | $7,269,000 |
| Other Gand A | $21,983,000 | $18,215,000 | $11,959,000 | $7,269,000 |
| Other Special Charges | - | $28,000,000 | - | - |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $15,348,000 | $6,724,000 | $49,906,000 | $46,239,000 |
| Total Assets | $50,243,000 | $36,862,000 | $53,948,000 | $48,992,000 |
| Total Non Current Assets | $199,000 | $252,000 | $0 | $6,000 |
| Current Assets | $50,044,000 | $36,610,000 | $53,948,000 | $48,986,000 |
| Other Current Assets | $1,788,000 | $515,000 | $1,099,000 | $80,000 |
| Receivables | $3,165,000 | $5,772,000 | $2,333,000 | $4,850,000 |
| Other Receivables | $1,170,000 | $2,209,000 | $1,407,000 | $3,552,000 |
| Accounts Receivable | $1,995,000 | $3,563,000 | $926,000 | $1,298,000 |
| Cash Cash Equivalents And Short Term Investments | $45,091,000 | $30,323,000 | $50,516,000 | $42,683,000 |
| Cash And Cash Equivalents | $45,091,000 | $30,321,000 | $50,501,000 | $42,634,000 |
| Prepaid Assets | - | - | $997,000 | $1,373,000 |
| Debt | ||||
| Total Debt | $1,129,000 | - | - | - |
| Long Term Debt And Capital Lease Obligation | $1,129,000 | - | - | - |
| Long Term Debt | $1,129,000 | - | - | - |
| Current Debt And Capital Lease Obligation | - | - | - | - |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $34,895,000 | $30,138,000 | $4,042,000 | $2,753,000 |
| Total Non Current Liabilities Net Minority Interest | $27,114,000 | $18,843,000 | $0 | $0 |
| Derivative Product Liabilities | $25,985,000 | $0 | - | $0 |
| Current Liabilities | $7,781,000 | $11,295,000 | $4,042,000 | $2,753,000 |
| Payables And Accrued Expenses | $7,781,000 | $11,293,000 | $3,968,000 | $2,753,000 |
| Payables | $3,293,000 | $3,148,000 | $2,153,000 | $1,384,000 |
| Accounts Payable | $3,293,000 | $3,148,000 | $2,153,000 | $1,069,000 |
| Other Current Liabilities | - | $2,000 | $74,000 | - |
| Total Tax Payable | - | - | $0 | $315,000 |
| Income Tax Payable | - | - | $0 | $315,000 |
| Equity | ||||
| Common Stock Equity | $15,348,000 | $6,724,000 | $49,906,000 | $46,239,000 |
| Total Equity Gross Minority Interest | $15,348,000 | $6,724,000 | $49,906,000 | $46,239,000 |
| Stockholders Equity | $15,348,000 | $6,724,000 | $49,906,000 | $46,239,000 |
| Retained Earnings | $-188,589,000 | $-138,998,000 | $-81,466,000 | $-71,480,000 |
| Preferred Securities Outside Stock Equity | $0 | $18,843,000 | $0 | - |
| Other | ||||
| Ordinary Shares Number | $69,894,507 | $31,574,657 | $23,977,491 | $20,861,315 |
| Share Issued | $69,894,507 | $31,574,657 | $23,977,491 | $20,861,315 |
| Tangible Book Value | $15,348,000 | $6,724,000 | $49,906,000 | $46,239,000 |
| Invested Capital | $16,477,000 | $6,724,000 | $49,906,000 | $46,239,000 |
| Working Capital | $42,263,000 | $25,315,000 | $49,906,000 | $46,233,000 |
| Total Capitalization | $16,477,000 | $6,724,000 | $49,906,000 | $46,239,000 |
| Additional Paid In Capital | $203,930,000 | $145,719,000 | $131,370,000 | $117,717,000 |
| Capital Stock | $7,000 | $3,000 | $2,000 | $2,000 |
| Common Stock | $7,000 | $3,000 | $2,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Accrued Expenses | $4,488,000 | $8,145,000 | $1,815,000 | $1,369,000 |
| Net PPE | $199,000 | $252,000 | $0 | $6,000 |
| Other Short Term Investments | $0 | $2,000 | $15,000 | $49,000 |
| Accumulated Depreciation | - | - | $-25,000 | $-19,000 |
| Gross PPE | - | - | $25,000 | $25,000 |
| Other Properties | - | - | $20,000 | $20,000 |
| Machinery Furniture Equipment | - | - | $5,000 | $5,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-35,253,000 | $-25,576,000 | $-1,112,000 | $14,314,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-35,253,000 | $-25,576,000 | $-1,112,000 | $14,314,000 |
| Cash Flow From Continuing Operating Activities | $-35,253,000 | $-25,576,000 | $-1,112,000 | $14,314,000 |
| Operating Gains Losses | $11,515,000 | $-2,519,000 | $-80,000 | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $1,210,000 | $0 | $0 |
| Cash Flow From Continuing Investing Activities | $0 | $1,210,000 | $0 | $0 |
| Net Other Investing Changes | - | $1,210,000 | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-152,000 | $-79,000 | $0 | - |
| Issuance Of Capital Stock | $34,784,000 | $4,497,000 | $9,227,000 | $4,428,000 |
| Financing Cash Flow | $50,023,000 | $4,186,000 | $8,979,000 | $3,786,000 |
| Cash Flow From Continuing Financing Activities | $50,023,000 | $4,186,000 | $8,979,000 | $3,786,000 |
| Net Other Financing Charges | $-1,301,000 | $-232,000 | $-278,000 | $-131,000 |
| Net Common Stock Issuance | $34,632,000 | $4,418,000 | $9,227,000 | $4,428,000 |
| Common Stock Issuance | $34,784,000 | $4,497,000 | $9,227,000 | $4,428,000 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | $9,000 |
| Income Tax Paid Supplemental Data | $0 | $0 | $344,000 | $0 |
| End Cash Position | $45,091,000 | $30,321,000 | $50,501,000 | $42,634,000 |
| Beginning Cash Position | $30,321,000 | $50,501,000 | $42,634,000 | $24,534,000 |
| Changes In Cash | $14,770,000 | $-20,180,000 | $7,867,000 | $18,100,000 |
| Proceeds From Stock Option Exercised | $16,692,000 | $0 | $30,000 | $27,000 |
| Common Stock Payments | $-152,000 | $-79,000 | $0 | - |
| Change In Working Capital | $-2,154,000 | $3,090,000 | $4,076,000 | $-5,555,000 |
| Change In Payables And Accrued Expense | $-3,488,000 | $5,895,000 | $1,205,000 | $-566,000 |
| Change In Accrued Expense | $-3,495,000 | $5,675,000 | $123,000 | $-51,000 |
| Change In Payable | $7,000 | $220,000 | $1,082,000 | $-515,000 |
| Change In Account Payable | $7,000 | $220,000 | $1,082,000 | $-515,000 |
| Change In Prepaid Assets | $-1,273,000 | $634,000 | $354,000 | $-139,000 |
| Change In Receivables | $2,607,000 | $-3,439,000 | $2,517,000 | $-4,850,000 |
| Changes In Account Receivables | $1,568,000 | $-2,637,000 | $372,000 | $-1,298,000 |
| Other Non Cash Items | $1,523,000 | $28,000,000 | $1,328,000 | - |
| Stock Based Compensation | $3,399,000 | $3,362,000 | $3,510,000 | $1,807,000 |
| Unrealized Gain Loss On Investment Securities | $2,000 | $13,000 | $34,000 | $170,000 |
| Depreciation Amortization Depletion | $53,000 | $10,000 | $6,000 | $4,000 |
| Depreciation And Amortization | $53,000 | $10,000 | $6,000 | $4,000 |
| Depreciation | $53,000 | $10,000 | $6,000 | $4,000 |
| Gain Loss On Investment Securities | $11,515,000 | $-72,000 | $-80,000 | - |
| Gain Loss On Sale Of PPE | $0 | $-2,447,000 | $0 | - |
| Net Income From Continuing Operations | $-49,591,000 | $-57,532,000 | $-9,986,000 | $17,888,000 |
| Gain Loss On Sale Of Business | - | $-2,447,000 | $0 | - |
| Repayment Of Debt | - | - | $0 | $-538,000 |
| Net Issuance Payments Of Debt | - | - | $0 | $-538,000 |
| Net Short Term Debt Issuance | - | - | $0 | $-538,000 |
| Short Term Debt Payments | - | - | $0 | $-538,000 |
| Issuance Of Debt | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-23